Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT

King Faisal Specialist Hospital & Research Center

Status: Completed

Conditions: Hodgkin Disease; Lymphoma, Non-Hodgkin

Treatments: Procedure: FDG PET

Study type: Interventional

Funder types: Other

Identifiers

NCT00534989

RAC#2041-050

Details and patient eligibility

About

Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma or Hodgkin's Disease

Enrollment: 10 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients with NHL and HD undergoing HDC and ASCT

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)